Inventor · disambiguated record
Vicken H. Karageozian
Also filed as: KARAGEOZIAN VICKEN · KARAGEOZIAN VICKEN H
14 granted patents·16 pending applications·511 citations·filing 1995–2025
94Inventor score
Files withALLEGRO PHARMACEUTICALS LLC9ISTA PHARMACEUTICALS INC4ADVANCED CORNEAL SYSTEMS2ALLEGRO PHARMACEUTICALS INC2JENIUS PHARMA LLC2
Top patents by PatentIndex Score
30 records- 0194US6537545B1Use of corneal hardening agents in enzymeorthokeratologyISTA PHARMACEUTICALS INC·Filed 2000·Granted Mar 25, 2003·108 cites·8 claims
- 0289US5866120AMethod for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidaseADVANCED CORNEAL SYSTEMS INC·Filed 1995·Granted Feb 2, 1999·76 cites·9 claims
- 0387US6863886B2Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disordersADVANCED CORNEAL SYSTEMS·Filed 2003·Granted Mar 8, 2005·29 cites·20 claims
- 0483US9896480B2Integrin receptor antagonists and their methods of useMACKEL MICHAEL JOHN·Filed 2012·Granted Feb 20, 2018·9 cites·28 claims
- 0583US5579201AModified electrical strip for energizing/de-energizing secondary devices simultaneously with a main deviceFiled 1995·Granted Nov 26, 1996·119 cites·8 claims
- 0682US6939542B2Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eyeISTA PHARMACEUTICALS INC·Filed 2003·Granted Sep 6, 2005·12 cites·18 claims
- 0782US6551590B2Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vireous body of the eyeISTA PHARMACEUTICALS INC·Filed 1999·Granted Apr 22, 2003·40 cites·17 claims
- 0881US10590166B2Peptides useable for treating cancerALLEGRO PHARMACEUTICALS LLC·Filed 2018·Granted Mar 17, 2020·3 cites·8 claims
- 0981US6610292B2Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disordersISTA PHARMACEUTICALS INC·Filed 1999·Granted Aug 26, 2003·54 cites·19 claims
- 1079US8691874B2Treatment of ophthalmic disorders using ureaKARAGEOZIAN VICKEN H·Filed 2012·Granted Apr 8, 2014·6 cites·36 claims
- 1178US7977385B2Agents for corneal or intrastromal administration to treat or prevent disorders of the eyeNUMODA BIOTECHNOLOGIES INC·Filed 2003·Granted Jul 12, 2011·22 cites·10 claims
- 1278US6039943AMethod for accelerating clearance of hemorrhagic blood from the vitreous body with hyaluronidaseADVANCED CORNEAL SYSTEMS·Filed 1998·Granted Mar 21, 2000·33 cites·17 claims
- 1371US2024382557A1Inhibition of tumor necrosis factor, pro-inflammatory cytokines and other inflammatory response mediatorsALLEGRO PHARMACEUTICALS LLC·Filed 2024·Application pending·0 cites
- 1468US12454549B2Treatments for diseases and disorders that involve oxidative stressJENIUS PHARMA LLC·Filed 2023·Granted Oct 28, 2025·0 cites·5 claims
- 1565US2022313771A1Inhibition of tumor necrosis factor, pro-inflammatory cytokines and other imflammatory response mediatorsALLEGRO PHARMACEUTICALS LLC·Filed 2022·Application pending·0 cites
- 1664US2020392181A1Peptide compositions and related methodsALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1764US2020354402A1Peptide compositions and related methodsALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 1863US2006034822A1Hyaluronidase preparation for ophthalmic administration and enzymatic methods for accelerating clearance of hemorrhagic blood from the vitreous body of the eyeKARAGEOZIAN HAMPAR L·Filed 2005·Application pending·0 cites
- 1963US2005069531A1Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disordersFiled 2004·Application pending·0 cites
- 2060US2021085749A1Therapeutic and Neuroprotective PeptidesALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 2159US2019062371A1Peptide compositions and related methodsALLEGRO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2257US2018207227A1Therapeutic and Neuroprotective PeptidesALLEGRO PHARMACEUTICALS INC·Filed 2018·Application pending·0 cites
- 2355US2025382328A1Treatments for diseases and disorders that involve oxidative stressJENIUS PHARMA LLC·Filed 2025·Application pending·0 cites
- 2454US2007105950A1Treatment of ophthalmic disorders using urea and urea derivativesVITREO RETINAL TECHNOLOGIES IN·Filed 2006·Application pending·0 cites
- 2553US2021275624A1Treatments for improving or lessening impairment of mitochondrial functionALLEGRO PHARMACEUTICALS LLC·Filed 2021·Application pending·0 cites
- 2652US2022031800A1Peptides for treating non-exudative macular degeneration and other disorders of the eyeALLEGRO PHARMACEUTICALS LLC·Filed 2020·Application pending·0 cites
- 2749US11673914B2Peptide therapies for reduction of macular thickeningALLEGRO PHARMACEUTICALS LLC·Filed 2020·Granted Jun 13, 2023·0 cites·15 claims
- 2849US2003199574A1Treatment of ophthalmic disorders using urea and urea derivativesVITREO RETINAL TECHNOLOGIES IN·Filed 2003·Application pending·0 cites
- 2947US2020345805A1Compositions and methods useable for treatment of dry eyeALLEGRO OPHTHALMICS LLC·Filed 2020·Application pending·0 cites
- 3045US2003175259A1Use of corneal hardening agents in enzymeorthokeratologyFiled 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →